hereby is, revoked. The Deputy Administrator further orders that any pending applications for renewal or modification of such registration be, and they hereby are, denied. This order is effective November 1, 2004.

Dated: September 8, 2004.

Michele M. Leonhart,

Deputy Administrator.

[FR Doc. 04–21959 Filed 9–29–04; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated May 5, 2004, and published in the **Federal Register** on May 26, 2004, (69 FR 29979), Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Methadone (9250)	II
Methadone Intermediate (9254)	II
Dextropropoxyphene (9273)	II
Levo-alphacetylmethadol (9648)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances for formulation into finished pharmaceuticals.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemicals Inc. to manufacture the basic classes of controlled substances listed is consistent with the public interest at this time. DEA has investigated Boehringer Ingelheim Chemicals Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: September 16, 2004,

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–21957 Filed 9–29–04; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated May 5, 2004 and published in the **Federal Register** on May 26, 2004, (69 FR 29978–29979), Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Driver, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The company plans to import Phenylacetone for the bulk manufacture of amphetamine.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Boehringer Ingelheim Chemicals, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: September 16, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–21958 Filed 9–29–04; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated May 21, 2004, and published in the **Federal Register** on June 3, 2004, (69 FR 31412), Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Methadone (9250) and Methadone Intermediate (9254), basic classes of controlled substances listed in Schedule II.

The company plans to manufacture the controlled substances for research and development purposes.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex North Brunswick, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: September 8, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–21949 Filed 9–29–04; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to 21 CFR 1301.33(a), this is notice that on July 7, 2004, Cambridge Isotope Laboratory, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of

the basic classes of controlled substances listed:

Drug	Schedule
Methaqualone (2565)	I
Dimethyltryptamine (7435)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Pentobarbital (2270)	II
Secobarbital (2315)	II
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzzoylecgonine (9180)	II
Methadone (9250)	II
Dextropropoxyphene (9273)	II
Morphine (9300)	II
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug analysis.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCD) and must be filed no later than November 29, 2004.

Dated: September 16, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–21947 Filed 9–29–04; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 03–27]

Paramabaloth Edwin, M.D.; Revocation of Registration

On April 24, 2003, the Deputy Administrator of the Drug Enforcement Administration (DEA), issued an Order to Show Cause/Immediate Suspension of Registration to Paramabaloth Edwin, M.D. (Dr. Edwin), notifying him of an opportunity to show cause as to why DEA should not revoke his DEA Certificate of Registration, AE7528295, as a practitioner, and deny any pending applications for renewal of registration pursuant to 21 U.S.C. 824(a)(4), for reason that Dr. Edwin's continued registration would be inconsistent with the public interest. The Order to Show Cause/Immediate Suspension of Registration further advised Dr. Edwin that his DEA Certification of Registration had been suspended, pursuant to 21 U.S.C. 824(d), as an imminent danger to public health and safety.

The Order to Show Cause/Immediate Suspension of Registration alleged, in part, that in August 2001, DEA had received information from a cooperating source that Dr. Edwin was selling and prescribing controlled substances for non-therapeutic uses. This information was corroborated by interviews of former patients, pharmacists and acquaintances of Dr. Edwin, as well as through a cooperating individual who purchased controlled substances from Dr. Edwin. It further alleged Dr. Edwin had purchased excessive quantities of controlled substances, stored controlled substances at an unregistered location and that his prescribing practices had hastened the addiction and/or death of patients.

Finally, it was alleged that on April 17, 2003, the Illinois Department of Professional Regulations (IDPR) summarily suspended Dr. Edwin's state medical and controlled substance licenses, thus rendering him without state authority to handle controlled substances.

By letter dated May 21, 2003, Dr. Edwin, through counsel, requested a hearing and on May 29, 2003, Presiding Administrative Law Judge Mary Ellen Bittner (Judge Bittner) ordered the parties to file prehearing statements. On June 13, 2003, in lieu of filing a prehearing statement, the Government filed a Motion for Summary Disposition, asserting Dr. Edwin was without authorization to handle controlled substances in the State of Illinois and as a result, further proceedings in the matter were not required. Attached to the Government's motion was a copy of the IDPR's Order dated April 17, 2003, directing Dr. Edwin to ''immediately surrender all indicia of licensure to the Department.''

On June 16, 2003, Judge Bittner issued a Memorandum to the Parties affording Dr. Edwin an opportunity to respond to the Government's motion. In his response, Dr. Edwin argued it would violate due process to summarily dispose of the case premised on the IDPR's Order, which, according to Dr. Edwin, was ''based on mere allegations, which have not yet been tested.'' Dr. Edwin further argued there had been no hearings before the IDPR in which he had been afforded a chance to present evidence or rebut the allegations against him. However, Dr. Edwin did not deny that his state professional licenses had been surrendered.

On July 18, 2003, Judge Bittner issued the Opinion and Recommended Decision of the Administrative Law Judge (Opinion and Recommended Decision). As part of her recommended ruling, Judge Bittner granted the Government's Motion for Summary Disposition, finding Dr. Edwin lacked authorization to handle controlled substances in Illinois, the jurisdiction in which he is registered with DEA.

In granting the Government's motion, Judge Bittner further recommended that Dr. Edwin's DEA registration be revoked and any pending applications for modification or renewal be denied. No exceptions to the Opinion and Recommended Decision were filed.

The Deputy Administrator has considered the record in its entirety and pursuant to 21 CFR 1316.67, hereby issues her final order based upon findings of fact and conclusions of law as hereinafter set forth. The Deputy Administrator adopts, in full, the Opinion and Recommended Decision of the Administrative Law Judge.

The Deputy Administrator finds that Dr. Edwin currently possesses DEA Certificate of Registration AE7528295, and is registered to handle controlled substances in the State of Illinois. The Deputy Administrator further finds that in response to allegations of professional misconduct, on April 17, 2003, the IDPR issued an order directing Dr. Edwin to surrender all professional licenses. There is no evidence before the Deputy Administrator that IDPR's Order has been lifted, stayed or modified. Therefore, the Deputy Administrator finds that Dr. Edwin is currently not licensed to practice medicine in Illinois and as a result, it is reasonable to infer he is also without authorization to handle controlled substances in that state.

DEA does not have statutory authority under the Controlled Substances Act to issue or maintain a registration if the applicant or registrant is without state authority to handle controlled substances in the state in which he conducts business. *See* 21 U.S.C. 802(21), 823(f) and 824(a)(3). This prerequisite has been consistently upheld. *See* Stephen J. Graham, M.D., 69 FR 11661 (2004); Dominick A. Ricci, M.D., 58 FR 51104 (1993); Bobby Watts, M.D., 53 FR 11919 (1988). Revocation is also appropriate when a state license has been suspended, but with the possibility of future reinstatement. *See* Alton E. Ingram, Jr., M.D., 69 FR 22562